Wang et al24 demonstrated that CHI3L1 is not only a noninvasive marker for assessing liver fibrosis before treatment in CHB patients, but also a potential marker for monitoring liver fibrosis changes during treatment. Here, CHI3L1 is linked to Hepatic fibrosis.